Misuse of the well-stirred model of hepatic drug clearance

Drug Metabolism and Disposition

Volumn 35, Issue 3, 2007, Pages 501-502

  Yang, Jiansong ^a   Jamei, Masoud ^a   Yeo, Karen R ^a   Rostami Hodjegan, Amin ^a,b   Tucker, Geoffrey T ^a,b  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CLEARANCE; ERYTHROCYTE; FIRST PASS EFFECT; IN VITRO STUDY; IN VIVO STUDY; LETTER; LIVER BLOOD FLOW; LIVER CLEARANCE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PRIORITY JOURNAL;

LIVER; LIVER CIRCULATION; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 33847411025     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013359     Document Type: Letter

References (15)

1. Blanchard N, Alexandre E, Abadie C, Lave T, Heyd B, Mantion G, Jaeck D, Richert L, and Coassolo P (2005) Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35:1-15.
2. Blanchard N, Richert L, Notter B, Delobel F, David P, Coassolo P, and Lave T (2004) Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur J Pharm Sci 23:189-199.
3. de Graaf IA, de Kanter R, de Jager MH, Camacho R, Langenkamp E, van de Kerkhof EG, and Groothuis GM (2006) Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction. Drug Metab Dispos 34:591-599.
4. Foti RS and Fisher MB (2004) Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding. Drug Metab Dispos 32:295-304.
5. Gillette JR (1971) Factors affecting drug metabolism. Ann NY Acad Sci 179:43-66.
6. Hinderling PH (1997) Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 49:279-295.
7. Kharasch ED, Hoffer C, Whittington D, and Sheffels P (2004a) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269.
8. Kharasch ED, Walker A, Hoffer C, and Sheffels P (2004b) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 76:452-466.
9. Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34:1175-1181.
10. Mohutsky MA, Chien JY, Ring BJ, and Wrighton SA (2006) Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharm Res (NY) 23:654-662.
11. Rowland M, Benet LZ, and Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136.
12. Strelevitz TJ, Foti RS, and Fisher MB (2006) In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334-1341.
13. Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K, Urae A, Higuchi S, and Sawada Y (2000) Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 49:49-58.
14. Valentin J (2002) Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Pergamon, Oxford, UK.
15. Wilkinson GR and Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.